MedTrace Logo

Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer

NCT01139138 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2017-11-06

No results posted yet for this study

Summary

This study will assess the safety of panitumumab, irinotecan and everolimus when given in combination to treat advanced colorectal cancer

Conditions

Interventions

DRUG

Panitumumab

Panitumumab 6mg/kg IV every 14 days

DRUG

Irinotecan

Irinotecan 200mg/m2 IV every 14 days

DRUG

Everolimus

Everolimus daily po (dosage varies with cohort)

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • The Queen Elizabeth Hospital

    lead OTHER

Principal Investigators

  • Amanda Townsend, MBBS · The Queen Elizabeth Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2015-08-31
Completion
2017-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01139138 on ClinicalTrials.gov